Cue Biopharma
CUE
89 hedge funds and large institutions have $246M invested in Cue Biopharma in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 30 increasing their positions, 30 reducing their positions, and 5 closing their positions.
132% more call options, than puts
Call options by funds: $1.73M | Put options by funds: $745K
14% more capital invested
Capital invested by funds: $216M → $246M (+$29.6M)
0% more funds holding
Funds holding: 89 → 89 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 30
0.18% less ownership
Funds ownership: 1.97% → 1.79% (-0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.21M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.09M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1M |
| 4 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$672K |
| 5 |
Morgan Stanley
New York
|
+$545K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$6.26M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$4.44M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.9M |
| 4 |
Goldman Sachs
New York
|
-$1.86M |
| 5 |
Millennium Management
New York
|
-$1.71M |
CUE Hedge Fund Activity: Q3 2021 in Review
89 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2021, worth a combined $246M — up 14% from $216M a quarter earlier.
Fund positioning in CUE was balanced in Q3 2021: 5 funds opened new positions, 5 closed out, 30 added to existing stakes and 30 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $1.21M. The largest seller was Corriente Advisors, cutting an estimated $6.26M.
- 89 institutional investors held Cue Biopharma (CUE) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $246M of Cue Biopharma stock for Q3 2021, up 14% quarter-over-quarter.
- 5 funds opened new Cue Biopharma positions in Q3 2021 and 5 closed out, a net change of 0 holders.
- The largest Cue Biopharma buyer in Q3 2021 was Dimensional Fund Advisors, an estimated $1.21M added.
- The largest Cue Biopharma seller in Q3 2021 was Corriente Advisors, an estimated $6.26M sold.
Based on aggregated 13F filings for Q3 2021.